Paul Herzich - 13 Feb 2024 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Role: Chief Technology Officer
Signature: /s/ David Tyronne Howton as attorney-in-fact for Paul Herzich
Issuer symbol: SLDB
Transactions as of: 13 Feb 2024
Net transactions value: $0
Form type: 4
Filing time: 16 Feb 2024, 11:02:36 UTC
Previous filing: 05 Dec 2023
Next filing: 04 Dec 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	SLDB	Common Stock						6,022	13 Feb 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SLDB	Employee Stock Option (Right to Buy)	Award	$0	+57,500		$0.000000	57,500	13 Feb 2024	Common Stock	57,500	$7.85	Direct	F2
transaction	SLDB	Restricted Stock Units	Award	$0	+28,750		$0.000000	28,750	13 Feb 2024	Common Stock	28,750		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 1,752 shares of the issuer's common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on November 30, 2023.
F2	This option was granted on February 13, 2024 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary.
F3	Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").
F4	The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.